Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study
| Autor: | Sunao Shoji, Masahiro Nitta, Yoshiaki Kawamura, Taro Higure, Hideshi Miyakita, Masanori Hasegawa, Akira Miyajima, Satoshi Kuroda, Yukio Usui, Hidenori Zakoji, Kentaro Nagao |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment 030232 urology & nephrology Urology Cystectomy 03 medical and health sciences 0302 clinical medicine Medicine Humans Radiology Nuclear Medicine and imaging Stage (cooking) Pathological Neoadjuvant therapy Aged Retrospective Studies Aged 80 and over Chemotherapy Carcinoma Transitional Cell Bladder cancer business.industry General Medicine Middle Aged medicine.disease Chemotherapy regimen Neoadjuvant Therapy Survival Rate Treatment Outcome Oncology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis T-stage Female business |
| Zdroj: | Japanese journal of clinical oncology. 50(1) |
| ISSN: | 1465-3621 |
| Popis: | Objective We evaluated the effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for urothelial bladder cancer. Methods We retrospectively examined 140 consecutive patients with muscle-invasive bladder cancer (clinical stage T2 to T4 and N0) who underwent radical cystectomy with or without neoadjuvant chemotherapy at four academic institutions between January 2006 and December 2016. Patients were categorized into the neoadjuvant chemotherapy group (those who underwent treatment with any neoadjuvant chemotherapy regimen; n = 69) and the non-neoadjuvant chemotherapy group (those who did not receive any neoadjuvant chemotherapy regimen; n = 71). The primary outcome measure was overall survival. Results The 5-year overall survival rates were 58.0% and 61.8% in the neoadjuvant chemotherapy and non-neoadjuvant chemotherapy groups, respectively (P = 0.320). The 5-year overall survival rates for the neoadjuvant chemotherapy and non-neoadjuvant chemotherapy groups were 64.8% and 68.4%, respectively, among cT2N0 patients (P = 0.688) and 38.6% and 21.6%, respectively, among cT3-4aN0 patients (P = 0.290). When patients with cT3-4aN0 disease in the neoadjuvant chemotherapy group were divided into responders ( Conclusion Among cT3-4aN0 patients, survival outcomes were significantly better in responders ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|